Some of the most common and targetable mutations in NSCLC include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, rearranged during transfection (RET) rearrangements, BRAF mutations, and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.